首页> 外文期刊>European journal of gastroenterology and hepatology >Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.
【24h】

Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.

机译:熊去氧胆酸可降低胆囊胆固醇结石患者的胆汁粘度和可沉积部分。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Ursodeoxycholic acid (UDCA) therapy is associated with reduced risk of biliary pain and acute cholecystitis or pancreatitis in patients with cholesterol gallstones. The underlying mechanisms are understood incompletely, which prompted us to study the influence of UDCA treatment on composition, viscosity and sedimentable fractions of gallbladder bile in 25 patients with symptomatic cholesterol gallstones. METHODS: In two randomised groups, either UDCA (750 mg daily) or placebo was given to each patient 10-12 days before cholecystectomy. Gallbladder bile was collected intraoperatively and analysed for protein, mucin, lipid composition, cholesterol crystal observation time, amount of cholesterol in vesicles, viscosity and sedimentable fractions (cholesterol, protein, mucin, bilirubin). RESULTS: UDCA-treated patients showed longer cholesterol crystal observation times and lower concentrations of total cholesterol and percentages of vesicular cholesterol in gallbladder bile. The concentrations of protein and mucin in gallbladder bile tended to be lower in the UDCA-treated group, but phospholipids, bile acids and bilirubin did not differ between the groups. Viscosity and the total sedimentable fractions of gallbladder bile decreased in the UDCA-treated patients. CONCLUSIONS: UDCA treatment reduces total and vesicular cholesterol, the formation of cholesterol crystals, viscosity, and the total amount of sedimentable fractions in gallbladder bile. These observations might explain, at least partially, why UDCA treatment attenuates the occurrence of biliary pain and complications in gallstone patients.
机译:目的:熊去氧胆酸(UDCA)治疗可降低胆固醇性胆结石患者胆痛和急性胆囊炎或胰腺炎的风险。尚未完全理解其潜在机制,这促使我们研究UDCA治疗对25例有症状胆固醇胆结石患者胆囊胆汁的组成,粘度和可沉积部分的影响。方法:在两个随机分组中,在胆囊切除术前10-12天向每位患者给予UDCA(每日750 mg)或安慰剂。术中收集胆囊胆汁,并分析蛋白质,粘蛋白,脂质组成,胆固醇晶体的观察时间,囊泡中胆固醇的含量,粘度和可沉积部分(胆固醇,蛋白质,粘蛋白,胆红素)。结果:UDCA治疗的患者胆囊胆汁中胆固醇晶体的观察时间更长,总胆固醇浓度和囊泡胆甾醇的百分比更低。 UDCA治疗组胆囊胆汁中蛋白质和粘蛋白的浓度趋于降低,但两组之间的磷脂,胆汁酸和胆红素没有差异。 UDCA治疗的患者胆囊胆汁的粘度和总可沉积分数降低。结论:UDCA治疗可降低胆囊胆汁中的总胆固醇和囊泡胆固醇,胆固醇晶体的形成,粘度以及可沉积部分的总量。这些观察结果至少可以部分解释为什么UDCA治疗可以减轻胆结石患者的胆道疼痛和并发症的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号